CoChat

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study

Open access
Riccardi, A, Mora, O, Tinelli, C, Valentini, D, Brugnatelli, S, Spanedda, R, De Paoli, A, Barbarano, L, Di Stasi, M, Giordano, M, Delfini, C, Nicoletti, G, Bergonzi, C, Rinaldi, E, Piccinini, L, Ascari, E · 2000 · British Journal of Cancer
Cited by 125

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval 0.57-2.42; P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months; P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1054/bjoc.1999.1087

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 125

Metadata

Authors
Riccardi, A., Mora, O., Tinelli, C., Valentini, D., Brugnatelli, S., Spanedda, R., De Paoli, A., Barbarano, L., Di Stasi, M., Giordano, M., Delfini, C., Nicoletti, G., Bergonzi, C., Rinaldi, E., Piccinini, L., & Ascari, E.
Venue
British Journal of Cancer
Published
2000-04
Volume
82
Issue
7
Pages
1254-1260
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1534366501
Cited by
125
References
2
FWCI
1.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. https://app.cochat.ai/papers/10.1054/bjoc.1999.1087
The paper
Riccardi, A., Mora, O., Tinelli, C., Valentini, D., Brugnatelli, S., Spanedda, R., De Paoli, A., Barbarano, L., Di Stasi, M., Giordano, M., Delfini, C., Nicoletti, G., Bergonzi, C., Rinaldi, E., Piccinini, L., & Ascari, E. (2000). Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. British Journal of Cancer. https://doi.org/10.1054/bjoc.1999.1087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.